Article
Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Molecular pharmacology - 1 Oct 1994
Nitiss J L, Vilalta P M, Wu H, McMahon J
Abstract excerpt
Anti-topoisomerase II agents represent a major class of anticancer therapeutic agents. Resistance to this class of agents can be mediated by several possible mechanisms. One mechanism may involve mutations in the structural gene(s) for topoisomerases, altering the drug sensitivity of the enzymes....
Topics
- Amino Acid Sequence
- Amsacrine
- Base Sequence
- DNA Gyrase
- DNA Topoisomerases, Type II
- Drug Resistance
- Etoposide
- Glycine
- Lysine
- Molecular Sequence Data
- Mutation
- Oligodeoxyribonucleotides
- Saccharomyces cerevisiae